Nexus BioPharma, Inc. Adds to Product Portfolio

HOUSTON, TX / ACCESSWIRE / December 1, 2017 / Nexus BioPharma, Inc. (OTC PINK: NEXS), (Nexus), a company specializing in the development of a weight loss drug therapy, announced today that it had entered into a license agreement giving it exclusive rights for the commercial development of KV-001, a novel preclinical therapy for the rapid reduction of adipose tissue.

“Nexus now has two preclinical agents in development for weight loss,” said Mr. Warren C. Lau, Chief Executive Officer and President of Nexus BioPharma, Inc. “Our first agent, NEX-001, will address the long term weight loss market, and KV-001 will address the acute care weight loss market.”

“Patients with very high Body Mass Indexes (BMI) are often not eligible for surgery even in life-threatening situations,” said Dr. Brad Thompson, Chief Executive Officer of Kickshaw Ventures Ltd. and co-inventor of KV-001. “There is a critical need for an agent that will very rapidly reduce BMI in order to allow these patients to undergo surgery.”

About Nexus BioPharma, Inc.
www.nexusbiopharma.com

Nexus BioPharma, Inc. is a preclinical stage biotechnology company developing new therapies and intellectual property from research and development activities for treating obesity and type 2 diabetes.

The company is developing a proprietary drug, NEX-001, that stimulates the adenosine monophosphate-activated protein kinase (AMPK) pathway, the same key metabolic pathway activated by intense physical exercise. When activated, results include increased metabolism, reduced fat mass, and improved blood chemistry.

The underlying biochemistry is described in an article from the journal Cell Metabolism by Claire C. Bastie, and Jeffrey E. Pessin, entitled, “Fyn-Dependent Regulation of Energy Expenditure and Body Weight Is Mediated by Tyrosine Phosphorylation of LKB1” (Cell Metab. 2010 Feb 3;11(2):113-24).

In completed pre-clinical trials of the pharmaceutical activation of the AMPK pathway, test subjects showed reduced fat mass with no loss of lean muscle mass, plus a higher rate of energy expenditure, increased insulin sensitivity, increased fatty acid oxidation, improved plasma and tissue triglyceride levels, with lower cholesterol. Upon translation of this pharmaceutical activation to humans, these effects are expected to have a significant impact on treating obesity and diabetes.

Cautionary Statement Regarding Forward-Looking Information

This press release may contain certain “forward-looking statements” relating to the business of Nexus BioPharma, and its subsidiary companies. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the impact of the proceeds from the private placement on the Company’s short term business and operations; the general ability of the Company to achieve its commercial objectives, including the ability of the Company to sustain growth; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact:

Warren C. Lau
Warren.lau@nexusbiopharma.com
(832) 758-7488

SOURCE: Nexus BioPharma, Inc.

ReleaseID: 483325